TLPH — Talphera, Inc.

Talphera, Inc. (TLPH) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Cash balance as of September 30, 2025: $21.3 million.
• Operating expenses (R&D and SG&A) for 2025: $3.4 million, down from $3.7 million in 2024.
• Excluding non-cash stock-based compensation, expenses were $3.3 million in 2025 compared to $3.5 million in 2024.
• Revised cash operating expense guidance for 2025: $14 million to $15 million, down from the previous range of $16 million to $17 million.

2. Strategic Updates and Business Highlights:

• Completed a $17 million financing in September 2025, including a $5 million strategic investment from CorMedix.
• Enrollment in the nephro study continues, with a focus on high-enrollment medical ICUs and nephrologists as principal investigators.
• Restructured the nephro clinical study to reduce the target patient number from 166 to 70, aiming to accelerate completion.
• Positive feedback from investigators indicates strong interest in Nefamostat as a preferred anticoagulant for CRRT.

3. Forward Guidance and Outlook:

• Anticipated completion of the nephro study has been pushed to 2026 due to delays in activating new clinical sites.
• Expect to provide updates once 35 patients or 50% of study enrollment is achieved.
• Potential FDA approval for NIAID expected in late 2026, contingent on achieving study endpoints and stock price conditions.

4. Bad News, Challenges, or Points of Concern:

• Delays in activating six new target clinical sites have pushed back the estimated study completion timeline.
• Only two out of six new sites have been activated, with the remaining four facing various approval delays.
• One site (Veterans Affairs Medical Center) experienced personnel cuts that added three to four months to its timeline for enrollment.
• The overall enrollment rate has not significantly increased, raising concerns about the pace of patient recruitment.

5. Notable Q&A Insights:

• Enrollment rates at existing sites remain stable, but new sites are not enrolling faster than anticipated.
• There are concerns about external factors, such as federal funding volatility, impacting clinical study operations, though most sites have not reported issues.
• The management remains optimistic about the quality and potential contributions of the new sites once activated.

In summary, while Talphera, Inc. has secured financing and is making progress in its nephro study, challenges related to site activation and enrollment pace could impact timelines for study completion and FDA approval. The company remains focused on addressing these challenges while maintaining a positive outlook on the potential market for Nefamostat.